Related Experiment Video
Updated: Aug 9, 2025
Delayed Intramyocardial Delivery of Stem Cells after Ischemia Reperfusion Injury in a Murine Model
Published on: September 3, 2020
SDF-1α-Releasing Microspheres Effectively Extend Stem Cell Homing after Myocardial Infarction
Karolina Bajdak-Rusinek1, Agnieszka Fus-Kujawa1, Piotr Buszman2,3
1Department of Medical Genetics, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-752 Katowice, Poland.
Insights
This study shows that using SDF-1α-releasing microspheres can improve stem cell therapy for ischemic heart disease. It helps retain stem cells longer, promoting heart repair after myocardial infarction.
Area of Science:
- Cardiovascular Research
- Regenerative Medicine
- Biomaterials Science
Background:
- Ischemic heart disease (IHD) poses a growing healthcare challenge, with increasing prevalence linked to an aging population.
- Conventional treatments for IHD have limitations, and post-infarction cardiac remodeling leads to long-term insufficiency.
- Stem cell migration and differentiation are natural cardiac repair processes, but occur slowly.
Purpose of the Study:
- To investigate the potential of stromal cell-derived factor 1-alpha (SDF-1α)-releasing microspheres as a novel therapy for IHD.
- To determine if sustained SDF-1α delivery can enhance stem cell homing and retention in ischemic cardiac tissue.
- To evaluate the impact of SDF-1α-releasing microspheres on factors involved in myocardial stem cell recruitment and repair.
Main Methods:
- Biodegradable microspheres were engineered to achieve controlled release of SDF-1α.
- SDF-1α-releasing microspheres were administered into the pericardial sac 14 days post-myocardial infarction in a preclinical model.
- Levels of exogenous and endogenous SDF-1α were measured, along with the expression of key stem cell-related factors (VEGFA, SCF, VCAMs).
Main Results:
- Controlled release of SDF-1α from microspheres significantly prolonged its presence in cardiac tissue compared to endogenous levels.
- Administration of SDF-1α-releasing microspheres increased the expression of vascular endothelial growth factor A (VEGFA), stem cell factor (SCF), and vascular cell adhesion molecules (VCAMs).
- These findings suggest enhanced recruitment and retention of endogenous stem cells at the site of cardiac injury.
Conclusions:
- Sustained delivery of SDF-1α via biodegradable microspheres represents a promising strategy to overcome limitations in current stem cell therapy for IHD.
- This approach can effectively promote the migration and retention of stem cells in ischemic cardiac tissue, facilitating heart repair.
- SDF-1α-releasing microspheres offer a potential therapeutic tool for improving cardiac regeneration after myocardial infarction.
Abstract:
Ischemic heart disease (IHD) is one of the main focuses in today's healthcare due to its implications and complications, and it is predicted to be increasing in prevalence due to the ageing population. Although the conventional pharmacological and interventional methods for the treatment of IHD presents with success in the clinical setting, the long-term complications of cardiac insufficiency are on a continual incline as a result of post-infarction remodeling of the cardiac tissue. The migration and involvement of stem cells to the cardiac muscle, followed by differentiation into cardiac myocytes, has been proven to be the natural process, though at a slow rate. SDF-1α is a novel candidate to mobilize stem cells homing to the ischemic heart. Endogenous SDF-1α levels are elevated after myocardial infarction, but their presence gradually decreases after approximately seven days. Additional administration of SDF-1α-releasing microspheres could be a tool for the extension of the time the stem cells are in the cardiac tissue after myocardial infarction. This, in turn, could constitute a novel therapy for more efficient regeneration of the heart muscle after injury. Through this practical study, it has been shown that the controlled release of SDF-1α from biodegradable microspheres into the pericardial sac fourteen days after myocardial infarction increases the concentration of exogenous SDF-1α, which persists in the tissue much longer than the level of endogenous SDF-1α. In addition, administration of SDF-1α-releasing microspheres increased the expression of the factors potentially involved in the involvement and retention of myocardial stem cells, which constitutes vascular endothelial growth factor A (VEGFA), stem cell factor (SCF), and vascular cell adhesion molecules (VCAMs) at the site of damaged tissue. This exhibits the possibility of combating the basic limitations of cell therapy, including ineffective stem cell implantation and the ability to induce the migration of endogenous stem cells to the ischemic cardiac tissue and promote heart repair.
